At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 637 enrolled
Drug / intervention
brinzolamide 1% ophthalmic suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A BIOEQUIVALENCE STUDY OF THE GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION COMPARED TO REFERENCE LISTED DRUG AZOPT® (BRINZOLAMIDE) OPHTHALMIC SUSPENSION 1% IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
In Brief
A Phase 2 clinical trial evaluating brinzolamide 1% ophthalmic suspension and Azopt 1% for Glaucoma and Open Angle or Ocular Hypertension. Completed, enrolled 637 participants across 1 site.
Detailed Summary
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open Angle or Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
Primary CompletionNov 2018
First PostedApr 2019
TodayJul 2026
First PostedApr 1, 2019
Enrollment StartFeb 28, 2018
Primary CompletionNov 17, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.3 years ago
Interventions
brinzolamide 1% ophthalmic suspensiondrug
brinzolamide 1% ophthalmic suspension
Azopt 1%drug
Azopt 1%, RLD